Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
Reversed Brexit: £250 million for Bart De Strooper's dementia research

The UK has pledged a budget of £250 million to the creation of the UK Dementia Research Institute (DRI). The institute hopes to assemble top-notch…


Apitope receives 12 million euros from Wales

The Belgian-British biotech company Apitope, which started as a spin-off of the Hasselt University in Diepenbeek, gets 12 million euros from an in…


Patent discussion knocks down UCB shares

Investors aren’t pleased with the news that UCB’s patent on its epilepsy medicine Vimpat is under assault again. The company’s shares dropped 6% w…

POPULAR TAGS

ADx NeuroSciences receives 850.000 EUR support from Flemish Government for tracking brain disorders

Written by DS on in the category news with the tags , .


Brain injuries, dementia and other neurological problems are often noticed too late. The damage is irrevocable. ADX Neurosciences S.A. is committed to developing biomarkers that can detect, with a simple blood test, neurodegeneration in an early stage. The Flemish government supports the innovative research of this biotech company.

With the grant of 850,000 euros ADx can expand its global leadership position as an innovator in the field of neurobiological markers.

In what way will ADx use the money from the Flemish Government over the next two years?

  1. The fine-tuning of a blood test that can detect neurodegeneration in an early stage
  2. Exploring a new development platform to significantly shorten the time between discovery of a marker and its commercialization
  3. The detection and discovery of new markers that play a crucial role in the faltering communication between brain cells

Why does the Flemish Government support this innovative company?

In only 5 years, ADx acquired a good global position in the challenging field of brain diseases such as Alzheimer's and Parkinson's. ADX has also managed to launch, with a previous grant, two new markers, neurogranin and BACE1, in collaboration with Prof. Bart De Strooper (KU Leuven - VIB) and Prof. Sebastiaan Engelborghs (UA). Both of these tests will play an important role in the development of new drugs for Alzheimer's disease. The Flemish Agency for Enterprise and Innovation (VLAIO) also gave the green light to this new, ambitious project.

Koen Dewaele, CEO ADX: "We are very pleased with this support! This strengthens our ambition to build a world-neurobiological company. Our new tests will help a better and quicker diagnosis and also assist pharmaceutical companies in their development of new drugs for neurological disorders such as Alzheimer's, Parkinson's and ALS. "

Read more about ADx

Read more about: , .

RELATED ARTICLES
Reversed Brexit: £250 million for Bart De Strooper's dementia research

The UK has pledged a budget of £250 million to the creation of the UK Dementia Research Institute (DRI). The institute hopes to assemble top-notch…


Apitope receives 12 million euros from Wales

The Belgian-British biotech company Apitope, which started as a spin-off of the Hasselt University in Diepenbeek, gets 12 million euros from an in…


Patent discussion knocks down UCB shares

Investors aren’t pleased with the news that UCB’s patent on its epilepsy medicine Vimpat is under assault again. The company’s shares dropped 6% w…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

GSK XpandInnovation KU Leuven UGent Itera Life Science Turnstone V-Bio Ventures Janssen Flanders.bio Biowin

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.